Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 2,629-2,640 of 4,306
Drug study icon
CompletedNCT01397786

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Birmingham
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States, Canada, Colombia, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
TerminatedNCT02968121

Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Garden Grove
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 64 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT01552772

Safety and Tolerability study of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole

This study is completed in the United States. It focuses on schizophrenia.

Multiple locations, including Anaheim
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 64 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT01879722

Safety study of Multiple Rising Doses of TAK- 063 in schizophrenia

This study is completed in the United States. It is testing Multiple Rising Doses of TAK- 063 for schizophrenia.

In Glendale
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
Takeda
Condition
Schizophrenia
Drug study icon
CompletedNCT03164876

Safety study of AUT00206 in schizophrenia

This study is completed in the United Kingdom. It is testing AUT00206 for schizophrenia.

In London
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 50 Years
Countries
United Kingdom
Sponsor
Autifony Therapeutics Limited
Condition
Schizophrenia
Drug study icon
SuspendedNCT02724917

Safety study of APN1125 in schizophrenia

This study is suspended in the United States. It is testing APN1125 for schizophrenia.

In Long Beach
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 45 Years
Countries
United States
Sponsor
CoMentis
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.